Effect of Dietary Silk Peptide on Obesity, Hyperglycemia, and Skeletal Muscle Regeneration in High-Fat Diet-Fed Mice.
Lee K., Jin H., Chei S., Oh HJ., Lee JY., Lee BY.
Animal Study on Type 2 Diabetes, published in Cells (2020) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- Cells (2020)
- Country
- Switzerland
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 32041272
- DOI
- 10.3390/cells9020377
Abstract (original English)
Obesity is associated with excess body fat accumulation that can cause hyperglycemia and reduce skeletal muscle function and strength, which characterize the development of sarcopenic obesity. In this study, we aimed to determine the mechanism whereby acid-hydrolyzed silk peptide (SP) prevents high-fat diet (HFD)-induced obesity and whether it regulates glucose uptake and muscle differentiation using in vivo and in vitro approaches. Our findings demonstrate that SP inhibits body mass gain and the expression of adipogenic transcription factors in visceral adipose tissue (VAT). SP also had an anti-diabetic effect in VAT and skeletal muscle because it upregulated glucose transporter type 4 (GLUT4) and uncoupling protein 3 (UCP3) expression. Furthermore, SP reduced ubiquitin proteasome and promoted myoblast determination protein 1 (MyoD)/myogenic factor 4 (myogenin) expression, implying that it may have potential for the treatment of obesity-induced hyperglycemia and obesity-associated sarcopenia.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.
Related research
- Level ASystematic ReviewEurope PMC
The Influence of GLP-1 Agonists on Human Mesenchymal Stem Cells: A Systematic Review
Systematic Review on Type 2 Diabetes, published in Stem Cell Rev Rep (2026) — summary generated from the PubMed abstract.
- 2026
Stem Cell Rev Rep2 citations - Level ASystematic ReviewEurope PMC
Dedifferentiation of Mature Adipocytes and Their Future Potential for Regenerative Medicine Applications
Systematic Review on Type 2 Diabetes, Chronic Wound, published in Biomedicines (2026) — summary generated from the PubMed abstract.
- 2026
Biomedicines - Level ASystematic ReviewEurope PMC
Consolidating Clinical Insights and Uncovering Novel Regulatory Mechanisms of Exosomal MicroRNAs in Obesity and Metabolic Dysfunction Associated Steatotic Liver Disease: A Systematic Review and Bioinformatics Analysis
Systematic Review on Type 2 Diabetes, Chronic Inflammation, published in Food Sci Nutr (2026) — summary generated from the PubMed abstract.
- 2026
Food Sci Nutr - Level AMeta-analysisEurope PMC
Autologous and allogeneic mesenchymal stem cell-based therapies for diabetes mellitus: A systematic review and meta-analysis
Meta-analysis on Type 2 Diabetes, Immune Modulation, published in World J Stem Cells (2025) — summary generated from the PubMed abstract.
- 2025
World J Stem Cells1 citations - Level ASystematic ReviewPubMed
Systematic Review: Exosomes as Molecular Messengers in the Development of Obesity-Related Complications in Children.
Systematic Review on Type 2 Diabetes, published in Curr Issues Mol Biol (2025) — summary generated from the PubMed abstract.
- 2025
Curr Issues Mol Biol - Level AMeta-analysisEurope PMC
Thiamine as a putative natural modulator of PPARγ: exploring a nutrient-based approach for type 2 diabetes
Meta-analysis on Type 2 Diabetes, published in Front Pharmacol (2025) — summary generated from the PubMed abstract.
- 2025
Front Pharmacol